News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225 Results
Type
Article (41)
Press Release (184)
Section
Business (115)
Deals (18)
Drug Development (29)
FDA (5)
Job Trends (6)
News (136)
Policy (4)
Tag
Academia (1)
Alliances (12)
Approvals (5)
Best Places to Work (4)
CAR-T (2)
Cell therapy (3)
Clinical research (19)
Collaboration (1)
COVID-19 (4)
Earnings (33)
Events (44)
Executive appointments (1)
FDA (6)
Funding (1)
Gene editing (2)
Gene therapy (2)
GLP-1 (2)
Healthcare (5)
Infectious disease (4)
IPO (17)
Job creations (2)
Layoffs (1)
Manufacturing (1)
Mergers & acquisitions (1)
NextGen Class of 2024 (7)
Non-profit (2)
People (56)
Phase I (12)
Phase II (14)
Phase III (5)
Preclinical (3)
Radiopharmaceuticals (1)
Real estate (6)
Regulatory (7)
Startups (2)
Vaccines (1)
Date
Today (1)
Last 7 days (1)
Last 30 days (3)
Last 365 days (19)
2024 (19)
2023 (1)
2022 (41)
2021 (58)
2020 (49)
2019 (24)
2018 (16)
2017 (6)
2016 (7)
2015 (4)
Location
Africa (1)
Asia (6)
Europe (159)
225 Results for "autolus".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
FDA Action Alert: Journey, Merus, PTC and Autolus
The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic leukemia.
November 4, 2024
·
4 min read
·
Tristan Manalac
Press Releases
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
November 11, 2024
·
18 min read
Business
BioNTech Inks $250M Deal with Autolus to Advance CAR-T Assets
BioNTech will pay $50 million in cash and purchase $200 million of Autolus Therapeutics’ shares to progress the companies’ respective CAR-T candidates to commercialization.
February 8, 2024
·
2 min read
·
Tyler Patchen
Business
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
BioNTech SE and Autolus Therapeutics plc announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.
February 8, 2024
·
14 min read
Drug Development
Autolus Meets Phase II Acute Lymphoblastic Leukemia Endpoint
Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.
December 9, 2022
·
3 min read
·
Alex Keown
Autolus Therapeutics to Participate in Conferences During April 2022
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that management will participate in three upcoming investor conferences.
March 29, 2022
·
1 min read
Autolus Therapeutics announces 2022 priorities
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its 2022 corporate priorities and provided guidance.
January 10, 2022
·
8 min read
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
Autolus Therapeutics plc today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading CAR T clinical candidate, Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia (ALL) patients.
March 31, 2022
·
5 min read
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
Autolus Therapeutics plc announced an agreement with Moderna, a biotechnology company pioneering messenger RNA therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.
August 2, 2021
·
4 min read
Business
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Autolus Therapeutics plc announced its operational and financial results for the fourth quarter and full year ended December 31, 2021.
March 10, 2022
·
20 min read
1 of 23
Next
